dragon 10

BPC-157 (10mg Vial) dosing protocol
10mg Nasal Spray

BPC - 157 10mg Nasal Spray

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a gastric protein sequence studied for tissue-healing and cytoprotective properties^[1]^[2]. Preclinical models demonstrate accelerated wound repair and anti-inflammatory activity^[3], though human clinical data remain limited to early-phase safety trials and small case reports^[4]^[5]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Reconstitute: Add 3.0 mL bacteriostatic water → 3.33 mg/mL concentration.
Typical daily range: 200–600 mcg once daily (gradual titration).
Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.3 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at −20 °C (−4 °F); after reconstitution, refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.

Educational guide for reconstitution and weekly dosing

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Week	Daily Dose (mcg)	Units (per injection) (mL)
Weeks 1–2	200 mcg (0.2 mg)	6 units (0.06 mL)
Weeks 3–4	400 mcg (0.4 mg)	12 units (0.12 mL)
Weeks 5–8+	600 mcg (0.6 mg)	18 units (0.18 mL)

Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per-injection units well above 5 for better accuracy. Dosing is extrapolated from preclinical models^[1]^[6]; human clinical validation remains limited.

Reconstitution Steps

Draw 3.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Plan based on an 8–16 week daily protocol with gradual titration.

Peptide Vials (BPC-157, 10 mg each):
- 8 weeks ≈ 3 vials (25.2 mg used)
- 12 weeks ≈ 5 vials (42 mg used)
- 16 weeks ≈ 6 vials (58.8 mg used)
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (5 vials): 15 mL → 2 × 10 mL bottles
- 16 weeks (6 vials): 18 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes

Concise summary of the once-weekly regimen.

Goal: Support tissue-healing and recovery processes based on preclinical evidence^[1]^[3].
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Dose Range: 200–600 mcg daily with gradual titration.
Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Suggested weekly titration approach from clinical trials.

Start: 200 mcg daily; increase by ~200 mcg every 2 weeks as tolerated.
Target: 400–600 mcg daily by Weeks 5–8+.
Frequency: Once per day (subcutaneous).
Cycle Length: 8–12 weeks; optional extension to 16 weeks.
Timing: Any consistent time; rotate injection sites.

Proper storage preserves peptide quality and stability.

Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
Allow vials to reach room temperature before opening to reduce condensation uptake.

Practical considerations for consistency and safety.

Use new sterile insulin syringes for each injection; dispose in a sharps container^[7].
Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation^[8].
Inject slowly; wait a few seconds before withdrawing the needle.
Document daily dose and site rotation to maintain consistency.
BPC-157 human data are preliminary; clinical decisions should involve qualified healthcare providers.

BPC-157 is a synthetic peptide corresponding to a partial sequence of human gastric juice protein^[2]. Preclinical studies suggest it modulates nitric oxide pathways and growth-factor expression to promote angiogenesis and collagen deposition in damaged tissues^[1]^[3]. Animal models report accelerated healing of gut, tendon, ligament, and muscle injuries^[6]. A Phase I oral safety trial has been completed^[9], and a small human case series reported improvements following intra-articular administration^[5]; however, large-scale controlled human efficacy data are not yet available.

Observations from preclinical and early clinical literature.

Supports tissue repair in gut, tendon, muscle, and skin injury models (animal data)^[1]^[3].
Demonstrates anti-inflammatory and cytoprotective properties in preclinical settings^[6].
Phase I safety studies report good tolerability with no serious adverse events at tested doses^[9].
Occasional mild injection-site reactions (redness, itch) may occur with subcutaneous administration.
Long-term human safety and efficacy remain under investigation^[4].

Complementary strategies for best outcomes.

Support recovery with adequate protein intake and micronutrient-rich foods.
Balance activity and rest to allow tissue adaptation without overuse.
Prioritize sleep and stress management to enhance natural healing processes.
Consult qualified healthcare providers for injury-specific rehabilitation guidance.

General subcutaneous guidance from clinical best-practice resources^[10]^[11].

Clean the vial stopper and skin with alcohol; allow to dry.
Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[10].
Do not aspirate for subcutaneous injections; inject slowly and steadily^[10].
Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[8].
Discard used syringes immediately in a sharps container per WHO guidelines^[7].

This content is for educational purposes only and is not medical advice, diagnosis, or treatment. BPC-157 remains investigational with limited human clinical data. For research use only. Not for human consumption.

References

— Klicek R et al. BPC-157 promotes colocutaneous fistula healing via NO-system modulation (rat model)

— Józwiak M et al. Multifunctionality and possible medical application of BPC-157: literature and patent review (2025)

— Sikiric P et al. BPC-157 stable gastric pentadecapeptide: novel therapy for wound healing and tissue repair

— Seiwerth S et al. BPC-157 and standard angiogenic growth factors: gastrointestinal tract healing and beyond

— Vasireddi N et al. Emerging use of BPC-157 in orthopaedic sports medicine: systematic review (2025)

— Chang CH et al. BPC-157 promotes tendon-to-bone healing in a rat rotator cuff model

— Guideline on safety-engineered syringes for IM, ID, and SC injections in health care settings (2016)

— How to give a subcutaneous injection (patient education resource)

— NCT02637284: PCO-02 Phase I safety and pharmacokinetics trial of oral BPC-157

— Vaccine administration: subcutaneous route (angle/site; no aspiration)

— Pharmacologic considerations of the subcutaneous route

— Sikiric P et al. Pentadecapeptide BPC-157: from GI tract to whole body healing

— BPC-157 (10 mg) product page (quality and batch documentation)

Mechanism Breakdown — 3rd Party Analysis

This video provides an external overview on BPC-157.

External Source

Titration schedule.

Standard research titration model. Adjust under qualified clinical observation only. Not for human therapeutic use.

Phase 01

Wk 1 — 4

6 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

12 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

18 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

20 units

Once daily

Optional research extension

Research use only.

DRAGON 10 is supplied strictly for in-vitro laboratory research and biochemical analysis. It is not intended for human consumption, diagnostic use, veterinary application or therapeutic administration of any kind.

Handling must be performed by qualified personnel in compliance with applicable institutional and jurisdictional safety standards. The information contained on this protocol sheet is provided for educational and reference purposes only and does not constitute medical advice.

Not for human use
Store at 2–8 °C, protected from light

Reconstitute under aseptic conditions
Document all research observations

Red Tier Catalogue

Explore the full British Dragon research line.

Premium-tier compounds engineered for serious metabolic, longevity and performance research programs.

dragon 10

BPC-157 (10mg Vial) dosing protocol10mg Nasal Spray

BPC - 157 10mg Nasal Spray

Table of Contents

Quickstart Highlights

Dosing & Reconstitution Guide

Standard / Gradual Approach (3 mL = ~3.33 mg/mL)

Reconstitution Steps

Supplies Needed

Protocol Overview

Dosing Protocol

Storage Instructions

Important Notes

How This Works

Potential Benefits & Side Effects

Lifestyle Factors

Injection Technique

Video

Important Note

References

Mechanism Breakdown — 3rd Party Analysis

Titration schedule.

Phase 01

Wk 1 — 4

6 units

Once daily

Initiation · tolerance assessment

Phase 02

Wk 5 — 8

12 units

Once daily

Standard titration step

Phase 03

Wk 9 — 12

18 units

Once daily

Maintenance evaluation

Phase 04

Wk 13+

20 units

Once daily

Optional research extension

Research use only.

Red Tier Catalogue

Explore the full British Dragon research line.

BPC-157 (10mg Vial) dosing protocol
10mg Nasal Spray